Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064142 · ClinicalTrials.gov registry record · Phase 2
Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00064142: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00064142 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00064142, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This phase II trial studies how well halofuginone hydrobromide works in treating patients with human immunodeficiency virus (HIV)-related Kaposi's sarcoma. Halofuginone hydrobromide ointment may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor.
Interventions
- OTHER laboratory biomarker analysis
- OTHER placebo
- OTHER pharmacological study
- DRUG halofuginone hydrobromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00064142
The ClinicalTrials.gov registry entry for NCT00064142 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00064142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00064142 about?
NCT00064142 is a clinical study titled "Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma". This phase II trial studies how well halofuginone hydrobromide works in treating patients with human immunodeficiency virus (HIV)-related Kaposi's sarcoma. Halofuginone hydrobromide ointment may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor.
What is the current status of trial NCT00064142?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2003-05.
What interventions are being tested in trial NCT00064142?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), pharmacological study (OTHER), halofuginone hydrobromide (DRUG).
Who is sponsoring clinical trial NCT00064142?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.